Levesque LE, Hanley JA, Kezouh A, Suissa S
Kicking off 2026: Sparked by the long-awaited rise of non-opioid treatments, the first-ever - will capitalize on Vertex's recent success to transform efficacy and tolerability of pain management with Nav 1.8 & beyond: With rising anticipation for new targets like tau and LRRK2, the & returns as your flagship end-to-end forum for building on anti-amyloid approvals and strengthening biomarker assessments to reinvigorate the neurodegenerative treatment landscape: Concentrating on earlier-stage innovation, will unite those dedicated to translating discoveries of glial biology and peripheral immune pathways into novel approaches to target neuroinflammation across the neurodegenerative disease spectrum: Full details of the 2026 event schedule can be found in your copy of the World CNS 2026 Prospectus below
Additionally, it may regulate oxidative stress and platelet activation in surgical process [36]
WNT signaling in bone homeostasis and disease: from human mutations to treatments
This immune-focused blend delivers IV fluids, vitamin C, zinc, and B vitamins
International Journal of Pharmaceutics 1999
